open access

Vol 15, No 4 (2018)
Prace poglądowe - nadesłane
Published online: 2018-11-27
Get Citation

Non-pharmacological action of drugs used in psychiatry

Władysław Sterna
Psychiatria 2018;15(4):220-227.

open access

Vol 15, No 4 (2018)
Prace poglądowe - nadesłane
Published online: 2018-11-27

Abstract

The effectiveness of psychiatric medication is well documented and proved. However only a few articles concern the psychotherapeutic approach to phenomenon occurring within farmacological treatment. In this paper author describes psychological aspects of medical treatment especially according to psychodynamic theory. Author emphasizes the necessity of integration between biological aspects of medical treatment and understanding its psychological meaning for patient. Treatment formula (integrated treatment or split treatment), patient’s characteristics, therapeutic relationship, doctor’s characteristics as well as his or her psychotherapeutic knowledge influence the effects of therapy. Author discusses possible negative outcomes of psychopharmacological treatment which may occur. At the end, several recommendations are stated in order to improve effectiveness of psychopharmacological treatment.

Abstract

The effectiveness of psychiatric medication is well documented and proved. However only a few articles concern the psychotherapeutic approach to phenomenon occurring within farmacological treatment. In this paper author describes psychological aspects of medical treatment especially according to psychodynamic theory. Author emphasizes the necessity of integration between biological aspects of medical treatment and understanding its psychological meaning for patient. Treatment formula (integrated treatment or split treatment), patient’s characteristics, therapeutic relationship, doctor’s characteristics as well as his or her psychotherapeutic knowledge influence the effects of therapy. Author discusses possible negative outcomes of psychopharmacological treatment which may occur. At the end, several recommendations are stated in order to improve effectiveness of psychopharmacological treatment.
Get Citation

Keywords

pharmacotherapy, psychotherapy, integration, combined treatment, psychodynamic psychopharmacotherapy

About this article
Title

Non-pharmacological action of drugs used in psychiatry

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 4 (2018)

Pages

220-227

Published online

2018-11-27

Bibliographic record

Psychiatria 2018;15(4):220-227.

Keywords

pharmacotherapy
psychotherapy
integration
combined treatment
psychodynamic psychopharmacotherapy

Authors

Władysław Sterna

References (39)
  1. Mintz DL. Teaching the prescriber's role: the psychology of psychopharmacology. Acad Psychiatry. 2005; 29(2): 187–194.
  2. Nevins DB. Psychoanalytic perspectives on the use of medication for mental illness. Bull Menninger Clin. 1990; 54(3): 323–339.
  3. Samochowiec J, Bieńkowski P. Diagnoza, leczenie, organizacja. Wybrane wytyczne Europejskiego Towarzystwa Psychiatrycznego (EPA). PTP , Kraków 2016.
  4. Ankarberg P, Falkenström F. Treatment of depression with antidepressants is primarily a psychological treatment. Psychotherapy (Chic). 2008; 45(3): 329–339.
  5. Sterna W. Sterna A. Psychiatra, psychoterapeuta czy może psychofarmakoterapeuta? Problem z identyfikacją. Psychiatria 2016; 13. ; 3: 153–158.
  6. Mintz D, Belnap B. A view from Riggs: treatment resistance and patient authority - III. What is psychodynamic psychopharmacology? An approach to pharmacologic treatment resistance. J Am Acad Psychoanal Dyn Psychiatry. 2006; 34(4): 581–601.
  7. Ströhle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. 2009; 116: 777–784.
  8. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002; 27(4): 250–257.
  9. Mintz DL, Flynn DF. How (not what) to prescribe: nonpharmacologic aspects of psychopharmacology. Psychiatr Clin North Am. 2012; 35(1): 143–163.
  10. Kirsch I, Moore TJ, Scoboria A. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment. 2002; 5: 23.
  11. McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological treatment of depression. J Affect Disord. 2006; 92(2-3): 287–290.
  12. Fisher S, Greenberg RP. The curse of the placebo: fanciful pursuit of a pure biological therapy. In: Greenberg RP, Greenberg RP. ed. From placebo to panacea. Wiley, New York 1997: 3–56.
  13. Schapira K, McClelland HA, Griffiths NR, et al. Study on the effects of tablet colour in the treatment of anxiety states. Br Med J. 1970; 1(5707): 446–449.
  14. de Craen AJ, Roos PJ, de Vries AL, et al. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ. 1996; 313(7072): 1624–1626.
  15. Waber RL, Shiv B, Carmon Z, et al. Commercial features of placebo and therapeutic efficacy. JAMA. 2008; 299(9): 1016–1017.
  16. Munich R. Treatment Resistance and Patient Authority. Journal of Psychiatric Practice. 2012; 18(1): 64–65.
  17. Murawiec S. Koncepcja psychodynamicznej psychofarmakologii D. Mintza i B. Belnap – omówienie w odniesieniu do pacjentów ujawniających oporność na leczenie. Psychiatria Polska. 2008; XLII(3): 323–333.
  18. Kahn DA. Medication consultation and split treatment during psychotherapy. J Am Acad Psychoanal. 1991; 19(1): 84–98.
  19. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989; 46(1): 89–99.
  20. Scott J, Williams JM, Brittlebank A, et al. The relationship between premorbid neuroticism, cognitive dysfunction and persistence of depression: a 1-year follow-up. J Affect Disord. 1995; 33(3): 167–172.
  21. Peselow ED, Robins CJ, Sanfilipo MP, et al. Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. J Abnorm Psychol. 1992; 101(3): 479–486.
  22. Sneed JR, Rutherford BR, Rindskopf D, et al. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry. 2008; 16(1): 65–73.
  23. McNair DM, Fisher S, Kahn RJ, et al. Drug-personality interaction in intensive outpatient treatment. Arch Gen Psychiatry. 1970; 22(2): 128–135.
  24. Beitman B, Beck N, Deuser W, et al. Patient stage of change predicts outcome in a panic disorder medication trial. Anxiety. 2013; 1(2): 64–69.
  25. Sullivan MD, Katon WJ, Russo JE, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract. 2003; 16(1): 22–31.
  26. Zuroff D, Koestner R, Moskowitz DS, et al. Autonomous motivation for therapy: A new common factor in brief treatments for depression. Psychotherapy Research. 2007; 17(2): 137–147.
  27. Murawiec S. Koncepcja psychodynamicznej psychofarmakologii D. Mintza i B. Belnap – omówienie w odniesieniu do pacjentów ujawniających oporność na leczenie. Psychiatria Polska. 2008, XLII. ; 3: 323–333.
  28. Murawiec S. Psychodynamiczna interpretacja działania leków psychotropowych. In: Murawiec S, Żechowski C. ed. Od neurobiologii do psychoterapii. Instytut Psychiatrii i Neurologii, Warszawa 2009: 140–219.
  29. Cabaniss D. Shifting gears: The challenge to teach students to think psychodynamically and psychopharmacologically at the same time. Psychoanalytic Inquiry. 2009; 18(5): 639–656.
  30. Plakun EM. A view from Riggs--treatment resistance and patient authority: I. A psychodynamic perspective on treatment resistance. J Am Acad Psychoanal Dyn Psychiatry. 2006; 34(2): 349–366.
  31. Raue PJ, Schulberg HC, Heo M, et al. Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study. Psychiatr Serv. 2009; 60(3): 337–343.
  32. Lin P, Campbell DG, Chaney EF, et al. The influence of patient preference on depression treatment in primary care. Ann Behav Med. 2005; 30(2): 164–173.
  33. Iacoviello BM, McCarthy KS, Barrett MS, et al. Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials. J Consult Clin Psychol. 2007; 75(1): 194–198.
  34. Woolley SB, Fredman L, Goethe JW, et al. Hospital patients' perceptions during treatment and early discontinuation of serotonin selective reuptake inhibitor antidepressants. J Clin Psychopharmacol. 2010; 30(6): 716–719.
  35. Ankarberg P, Falkenström F. Treatment of depression with antidepressants is primarily a psychological treatment. Psychotherapy (Chic). 2008; 45(3): 329–339.
  36. Warden D, Trivedi MH, Wisniewski SR, et al. Identifying risk for attrition during treatment for depression. Psychother Psychosom. 2009; 78(6): 372–379.
  37. Aikens JE, Nease DE, Klinkman MS. Explaining patients' beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med. 2008; 6(1): 23–29.
  38. Van Egmond J, Kummeling I, Balkom TA. Secondary gain as hidden motive for getting psychiatric treatment. Eur Psychiatry. 2005; 20(5-6): 416–421.
  39. Waldinger RJ, Frank AF. Clinicians' experiences in combining medication and psychotherapy in the treatment of borderline patients. Hosp Community Psychiatry. 1989; 40(7): 712–718.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Psychiatria dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl